Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ACOG
SELLAlpha Cognition Inc. Common Stock · Healthcare · United States · $172M · Avg Vol: $595K/d
COMPANY DESCRIPTION
Alpha Cognition Inc. is a biopharmaceutical company focused on developing novel diagnostic and therapeutic agents for neurodegenerative diseases, particularly Alzheimer's and ALS. It advances a proprietary diagnostic and therapeutic platform targeting specific biomarkers, aiming to provide earlier detection and more effective treatments for challenging neurological conditions. The company is a clinical-stage biotechnology firm specializing in neurodegenerative disorders, addressing significant unmet medical needs through innovative approaches.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 0 | 0 | 0 | 10.2M | — | 10.8M | 22.2M | — | 117.2% |
| EPS | — | -0.56 | -0.83 | -2.04 | -1.17 | — | -1.39 | -1.29 | -0.63 | — |
| Shares | — | 21.8M | 21.8M | 16.0M | 21.7M | -0.1% | 21.8M | — | — | — |
| Debt | 1.1M | 1.2M | 1.2M | 0.9M | — | -5.4% | — | — | — | — |
| Equity | — | -1.3M | -4.7M | 39.1M | 62.5M | 59.9% | — | — | — | — |
| Op CF | — | -9.2M | -8.8M | -7.8M | -20.4M | — | -30.1M | — | — | — |
| Inv CF | — | -4.9K | 0 | -26.7K | -0.3M | — | — | — | — | — |
| Fin CF | — | 24.8K | 8.2M | 54.9M | 38.2M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ACOG are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ACOG | Alpha Cognition Inc. Common Stock(you) | $172M | 26 | SELL |
| KPTI | Karyopharm Therapeutics Inc. | $168M | 24 | SELL |
| NRXP | NRx Pharmaceuticals, Inc. | $161M | 27 | SELL |
| EQ | Equillium, Inc. | $157M | 23 | SELL |
| NKTX | Nkarta, Inc. | $162M | 29 | SELL |
| WHWK | Whitehawk Therapeutics, Inc. | $183M | 31 | SELL |
| MGNX | MacroGenics, Inc. | $235M | 25 | SELL |
| CUE | Cue Biopharma, Inc. | $135M | 30 | SELL |
| OBIO | Orchestra BioMed Holdings, Inc. | $224M | 21 | SELL |
| ANTX | AN2 Therapeutics, Inc. | $177M | 35 | SELL |
Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.5%